AS03B-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial

Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France

(2013) Yves Dauvilliers et al.   BRAIN

Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination

(2013) A. Szakacs et al.   NEUROLOGY

Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A

(2013) M.S. Heier et al.   SLEEP MEDICINE

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

(2013) E. Miller et al.   BMJ-British Medical Journal

H5N1 Avian Influenza in Children

(2012) A. F. Oner et al.   CLINICAL INFECTIOUS DISEASES

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

(2012) Hanna Nohynek et al.   PLoS One

The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns

(2012) Leonoor Wijnans et al.   VACCINE

Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china

(2011) Fang Han et al.   ANNALS OF NEUROLOGY

AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age

(2010) François Roman et al.   CLINICAL INFECTIOUS DISEASES

Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults

(2010) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study

(2010) Elizabeth Miller et al.   LANCET

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data

(2009) Geert Leroux-Roels   EXPERT OPINION ON BIOLOGICAL THERAPY

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials

(2009) Eric Plennevaux et al.   LANCET

Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009

(2009) Seema Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

(2009) Isabel Leroux-Roels et al.   VACCINE

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine

(2008) Isabel Leroux-Roels et al.   PLoS One

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

(2008) Hans C. Rümke et al.   VACCINE

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children

(2008) Terry Nolan et al.   VACCINE